Pharmacological studies on a new specifically potent antitussive agent, 14-hydroxydihydro-6 beta-thebainol-4-methylether (oxymethebanol).
D000700:Analgesics / Q000494:pharmacology; D000818:Animals; D000996:Antitussive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000633:toxicity; D001158:Arteries; D001466:Barium Sulfate; D001794:Blood Pressure / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D002415:Cats; D003061:Codeine / Q000494:pharmacology* / Q000633:toxicity; D003371:Cough / Q000517:prevention & control; D003864:Depression, Chemical; D004285:Dogs; D004639:Emetics / Q000494:pharmacology*; D004987:Ethers / Q000008:administration & dosage / Q000494:pharmacology / Q000633:toxicity; D005769:Gastrointestinal Motility / Q000187:drug effects; D006168:Guinea Pigs; D006801:Humans; D051379:Mice; D009019:Morphinans / Q000494:pharmacology*; D010710:Phosphates / Q000494:pharmacology; D051381:Rats; D012119:Respiration / Q000187:drug effects; D013375:Substance Withdrawal Syndrome
D000700:Analgesics; D000996:Antitussive Agents; D004639:Emetics; D004987:Ethers; D009019:Morphinans; D010710:Phosphates; D001466:Barium Sulfate; D003061:Codeine